These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 14961027)

  • 1. Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
    Chand M; Thakuri M; Keung YK
    Leukemia; 2004 Apr; 18(4):886-7; author reply 887-8. PubMed ID: 14961027
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.
    Luo Y; Lai XY; Tan YM; Shi JM; Zhao YM; Han XY; Zheng GF; Zhu XL; Sun J; Zheng YL; Wu GQ; He JS; Chen SY; Jin AY; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H
    Leukemia; 2009 Jun; 23(6):1171-4. PubMed ID: 19194468
    [No Abstract]   [Full Text] [Related]  

  • 3. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
    Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
    Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
    J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
    Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
    Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil.
    Silveira CA; Daldegan MB; Ferrari I
    Genet Mol Res; 2011 Sep; 10(3):2038-48. PubMed ID: 21968620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.
    Kata D; Mrówka-Kata K; Seweryn M; Pajak J; Najda J; Kyrcz-Krzemień S
    Leuk Res; 2010 Sep; 34(9):e229-31. PubMed ID: 20359744
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
    Jørgensen HG; Copland M; Holyoake TL
    Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib alone and in combination for chronic myeloid leukemia.
    Druker BJ
    Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
    Osorio S; Noblejas AG; Durán A; Steegmann JL
    Am J Hematol; 2007 May; 82(5):394-5. PubMed ID: 17117416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study.
    Sánchez-Guijo FM; Durán S; Galende J; Boqué C; Nieto JB; Balanzat J; Gracia A; García I; Avellaneda-Molina C; Moreno MV; Luño-Fernandez E; Hermosilla M; Sanchez-Varela JM; Dios A; López-Garrido P; Giraldo P; Bargay J; Domingo JM; Soler A; Salinas R; del Cañizo MC
    Leuk Res; 2011 Sep; 35(9):1184-7. PubMed ID: 21316760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
    Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
    Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.
    Roy L; Guilhot J; Martineau G; Larchée R; Guilhot F
    Leukemia; 2005 Sep; 19(9):1689-92. PubMed ID: 16015386
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
    N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of skin pigment caused by imatinib therapy.
    McPartlin S; Leach M
    Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.
    Pilot PR; Sablinska K; Owen S; Hatfield A
    Leukemia; 2006 Jan; 20(1):148; author reply 149. PubMed ID: 16292349
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 20. CML clonal evolution with resistance to single agent imatinib therapy.
    Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
    Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.